Technical Analysis for TCRT - Alaunos Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 2.11 | 0.00% | 0.00 |
TCRT closed down 1.4 percent on Tuesday, November 19, 2024, on 34 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -1.40% | |
| Inside Day | Range Contraction | -1.40% | |
| Fell Below 20 DMA | Bearish | 0.96% | |
| Gapped Up | Strength | 0.96% | |
| Down 3 Days in a Row | Weakness | 0.96% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 13 minutes ago |
| 20 DMA Resistance | 13 minutes ago |
| 10 DMA Resistance | 13 minutes ago |
| 1.5x Volume Pace | 13 minutes ago |
| Outside Day | 13 minutes ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, targeting common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR. The Company has clinical and strategic collaborations with The University of Texas MD Anderson Cancer Center and the National Cancer Institute.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Cell Therapy Epidermal Growth Factor Receptor Oncogenes National Cancer Institute P53 Ras Gtpase Tumor Suppressor Genes University Of Texas Md Anderson Cancer Center
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Cell Therapy Epidermal Growth Factor Receptor Oncogenes National Cancer Institute P53 Ras Gtpase Tumor Suppressor Genes University Of Texas Md Anderson Cancer Center
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 32.85 |
| 52 Week Low | 1.95 |
| Average Volume | 20,643 |
| 200-Day Moving Average | 8.84 |
| 50-Day Moving Average | 2.45 |
| 20-Day Moving Average | 2.14 |
| 10-Day Moving Average | 2.18 |
| Average True Range | 0.22 |
| RSI (14) | 45.36 |
| ADX | 16.44 |
| +DI | 31.08 |
| -DI | 20.31 |
| Chandelier Exit (Long, 3 ATRs) | 2.21 |
| Chandelier Exit (Short, 3 ATRs) | 2.60 |
| Upper Bollinger Bands | 2.42 |
| Lower Bollinger Band | 1.87 |
| Percent B (%b) | 0.44 |
| BandWidth | 25.70 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.09 |
| MACD Histogram | 0.029 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.35 | ||||
| Resistance 3 (R3) | 2.38 | 2.33 | 2.31 | ||
| Resistance 2 (R2) | 2.33 | 2.27 | 2.31 | 2.30 | |
| Resistance 1 (R1) | 2.22 | 2.23 | 2.19 | 2.19 | 2.29 |
| Pivot Point | 2.16 | 2.16 | 2.15 | 2.15 | 2.16 |
| Support 1 (S1) | 2.06 | 2.10 | 2.03 | 2.03 | 1.93 |
| Support 2 (S2) | 2.00 | 2.06 | 1.99 | 1.92 | |
| Support 3 (S3) | 1.89 | 2.00 | 1.91 | ||
| Support 4 (S4) | 1.87 |
